More recently, studies from our laboratory using APP-PSEN1-SREBF2 mice—a mouse model of Alzheimer's disease that overexpress the sterol regulatory element-binding transcription factor 2 (SREBF2)―have demonstrated that amyloid beta (Aβ) inhibits ATG4 activity and high brain cholesterol levels potentiate this inhibitory effect by reducing the mitochondrial GSH content [88]. This evidence concerns the gene SREBF2 and early-onset autosomal dominant Alzheimer disease.